DRISDOL
Details
- Status
- Prescription
- First Approved
- 1941-01-11
- Routes
- ORAL
- Dosage Forms
- CAPSULE
DRISDOL Approval History
What DRISDOL Treats
3 indicationsDRISDOL is approved for 3 conditions since its original approval in 1941. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Hypoparathyroidism
- Rickets
- Familial Hypophosphatemia
Drugs Similar to DRISDOL
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
DRISDOL FDA Label Details
ProIndications & Usage
Ergocalciferol is indicated for use in the treatment of hypoparathyroidism, refractory rickets, also known as vitamin D resistant rickets, and familial hypophosphatemia.
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.